This topic contains a solution. Click here to go to the answer

Author Question: Within a synaptic gap, monoamines are deactivated in the synaptic gap by a. reuptake. b. ... (Read 84 times)

james9437

  • Hero Member
  • *****
  • Posts: 568
Within a synaptic gap, monoamines are deactivated in the synaptic gap by
 
  a. reuptake.
 b. diffusion.
 c. enzymes.
 d. enzymes and reuptake.

Question 2

Which of the following neurotransmitters is an indoleamine?
 
  a. epinephrine
 b. norepinephrine
  c. serotonin
 d. dopamine



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Kaytorgator

  • Sr. Member
  • ****
  • Posts: 345
Answer to Question 1

a

Answer to Question 2

c




james9437

  • Member
  • Posts: 568
Reply 2 on: Jun 21, 2018
YES! Correct, THANKS for helping me on my review


Sarahjh

  • Member
  • Posts: 370
Reply 3 on: Yesterday
Wow, this really help

 

Did you know?

In 1864, the first barbiturate (barbituric acid) was synthesized.

Did you know?

Vital signs (blood pressure, temperature, pulse rate, respiration rate) should be taken before any drug administration. Patients should be informed not to use tobacco or caffeine at least 30 minutes before their appointment.

Did you know?

Signs of depression include feeling sad most of the time for 2 weeks or longer; loss of interest in things normally enjoyed; lack of energy; sleep and appetite disturbances; weight changes; feelings of hopelessness, helplessness, or worthlessness; an inability to make decisions; and thoughts of death and suicide.

Did you know?

Certain chemicals, after ingestion, can be converted by the body into cyanide. Most of these chemicals have been removed from the market, but some old nail polish remover, solvents, and plastics manufacturing solutions can contain these substances.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library